What one share of AEON Biopharma holds
AEON is a biopharmaceutical company advancing its proprietary botulinum toxin complex ABP-450 as a biosimilar to Botox® (onabotulinumtoxinA) with the goal of achieving full-label United States (“U.S.”) market entry for debilitating medical conditions.
AEON Biopharma’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.91 |
|---|---|
| Cash and investments | $0.13 |
| Debt | $0.07 |
| Book value | −$0.58 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | — | $72.93 | — | — | — | −$51.43 |
| 2025 | — | −$3.95 | $0.00 | −$1.74 | — | −$4.55 |
Common questions about AEON Biopharma
How much does one share of AEON Biopharma earn?
Over the last 12 months, AEON Biopharma lost $1.91 for each share.
Does AEON Biopharma pay a dividend?
AEON Biopharma didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is AEON Biopharma’s book value per share?
AEON Biopharma’s book value is negative (−$0.58 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of AEON Biopharma have?
Each share of AEON Biopharma has $0.13 of cash and investments and $0.07 of debt, as of June 30, 2026.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.